Comparison Of Prognosis İn Cases With Endometrioid Ovarian Cancer And Clear Cell Ovarian Cancer

Year 2024, Volume: 8 Issue: 1, 58 - 65, 30.04.2024

Sümeyye Yılmaz

https://doi.org/10.34084/bshr.1465417

Abstract

Objective: This study aims to compare the characteristics, clinical approaches, and survival outcomes between cases of endometrioid ovarian cancer (EnOC) and clear cell ovarian cancer (CCOC), referred to as endometriosis-related cancers.
Material And Method: This retrospective analysis involved the medical records of 46 patients with EnOC and 32 patients with CCOC. All patients underwent surgical treatment at the Gynecology Oncology Clinic of Ankara Dr. Zekai Tahir Burak Women's Health Training and Research Hospital. This study involved collecting and comparing demographic, clinicopathological, and survival data between the two groups.
Results: The analysis revealed a significantly lower 5-year disease-free survival rate in the CCOC group compared to the EnOC group (p = 0.027). In early-stage diagnoses (stage I-II), the 5-year disease-free and overall survival rates were comparable between the two groups. However, for patients diagnosed with CCOC at an advanced stage (stage III-IV), there was a significant decrease in the 5-year overall survival rate (p = 0.043). The incidence of endometriosis was similar in both cancer types. Patients with EnOC accompanied by endometriosis showed better 5-year overall and disease-free survival rates. Conversely, these survival rates in CCOC patients, whether with or without endometriosis, showed no significant difference.
Conclusion: EnOC, when associated with endometriosis, generally has a better prognosis. In early stages, CCOC and EnOC present similar prognoses. However, in advanced stages, the prognosis for CCOC is poorer prognosis compared to EnOC. Irrespective of the stage, the 5-year disease-free survival rate for CCOC is consistently lower than that for EnOC.

Keywords

Endometrioid ovarian cancer, clear cell ovarian cancer, endometriosis, prognosis

Project Number

30.12.2015/13

Endometrioid Over Kanseri ile Berrak Hücreli Over Kanseri Olan Olguların Prognozlarının Karşılaştırılması

Abstract

Amaç: Endometriozis ilişkili kanserler olarak adlandırılan endometrioid over kanseri (EnOK) ve berrak hücreli over kanseri (BHOK) olgularının özellikleri, klinik yaklaşımları ve sağ kalımlarının incelenmesi amaçlanmıştır.
Materyal ve Metod: Ankara Dr. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi Jinekolojik Onkoloji Kliniği’nde opere edilmiş endometrioid over kanseri (n=46) ve berrak hücreli over kanseri tanısı alan (n=32) olguların verileri retrospektif olarak hasta dosyalarından tarandı. Demografik, klinikopatolojik ve sağ kalım verileri toplanarak iki grup arasında prognoz karşılaştırıldı.
Bulgular: BHOK grubunda 5 yıllık hastalıksız sağ kalımın EnOK grubuna göre istatistiksel olarak anlamlı düzeyde azaldığı bulundu (p=0.027). Erken evrede (evre 1-2) tanı alan olgularda 5 yıllık hastalıksız sağ kalım ve genel sağ kalımın benzer olduğu görüldü. İleri evrede (evre 3-4) tanı alan BHOK olgularında ise 5 yıllık genel sağ kalımın istatistiksel olarak anlamlı düzeyde azaldığı bulundu (p=0.043). EnOK ve BHOK olgularında benzer oranda endometriozis olduğu görüldü. Endometriozis olan EnOK olgularında 5 yıllık genel sağ kalım ve hastalıksız sağ kalımın daha iyi olduğu, endometriozis olan ve olmayan BHOK olgularında ise 5 yıllık genel sağ kalım ve hastalıksız sağ kalımın farklı olmadığı bulundu.
Sonuç: Endometriozis ilişkili endometrioid over kanserinin prognozu daha iyidir. Erken evrede berrak hücreli over kanseri ve endometrioid over kanserinin prognozlarının benzer olduğu, ileri evrede berrak hücreli over kanserinin prognozunun endometrioid over kanserine göre daha kötü olduğu ve evreden bağımsız berrak hücreli over kanserinin 5 yıllık hastalıksız sağ kalımın endometrioid over kanserinden daha kötü olduğu gözükmektedir.

Keywords

Endometrioid over kanseri, berrak hücreli over kanseri, endometriozis, prognoz

Ethical Statement

Ankara Dr. Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanesi Eğitim Planlama ve Koordinasyon Kurulu’ndan (EPK) çalışma için onay alındı. (EPK numarası: 30.12.2015/13)

Project Number

30.12.2015/13

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: a cancer journal for clinicians, 2011, 61(2), 69-90.
• Whittemore AS, Balise RR, Pharoah PDP, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British journal of cancer, 2004, 91(11), 1911-1915.
• Quirk, JT, Natarajan N, Ovarian cancer incidence in the United States, 1992–1999. Gynecologic oncology, 2005, 97(2), 519-523.
• Nagle CM, Olsen CM, Webb PM, et al. Australian Ovarian Cancer Study Group. Endometrioid and clear cell ovarian cancers–A comparative analysis of risk factors. European journal of cancer, 2008, 44(16), 2477-2484.
• Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert review of molecular diagnostics, 2009, 9(6), 555-566.
• Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. Journal of clinical oncology, 1991, 9(7), 1138-1150.
• Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecologic oncology, 2008, 109(3), 370-376.
• Keles E, Kabaca C, Giray B. High-grade serous carcinoma arising in postmenopausal ovarian endometrioma: A rarely encountered case. Sakarya Tıp Dergisi, 2022 12(3), 577-580.
• Kim HS, Kim MA, Lee M, et al. Effect of endometriosis on the prognosis of ovarian clear cell carcinoma: a two-center cohort study and meta-analysis. Annals of surgical oncology, 2015, 22, 2738-2745.
• Kim HS, Kim TH, Chung HH, et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. British journal of cancer, 2014, 110(7), 1878-1890.
• Yang B, Wang D, Chen H, et al. The association between endometriosis and survival outcomes of ovarian cancer: Evidence based on a meta analysis. Nigerian Journal of Clinical Practice, 2015, 18(5), 577-583.
• Hermens M, van Altena AM, van der Aa M, et al. Ovarian cancer prognosis in women with endometriosis: a retrospective nationwide cohort study of 32,419 women. American Journal of Obstetrics and Gynecology, 2021, 224(3), 284-e1.
• Li Q, Sun Y, Zhang X, et al. Endometriosis-associated ovarian cancer is a single entity with distinct clinicopathological characteristics. Cancer biology & therapy, 2019, 20(7), 1029-1034.
• Ju UC, Kang WD, Kim SM. The effect of concurrent endometriosis on the prognosis of women with ovarian clear cell or endometrioid carcinoma. International Journal of Gynecology & Obstetrics, 2019, 146(2), 177-183.
• Davis M, Rauh-Hain JA, Andrade C, et al. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecologic oncology, 2014, 132(3), 760-766.
• Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. The lancet oncology, 2012, 13(4), 385-394.
• Lyttle B, Bernardi L, Pavone ME. Ovarian cancer in endometriosis: clinical and molecular aspects. Minerva ginecologica, 2014, 66(2), 155.
• Cuff J, Longacre TA. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type. The American journal of surgical pathology, 2012, 36(5), 688-695.
• Scarfone G, Bergamini A, Noli S, et al. Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study. Gynecologic oncology, 2014, 133(3), 480-484.
• Kurman RJ, Shih IM. Pathogenesis of ovarian cancer. Lessons from morphology and molecular biology and their clinical implications. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists, 2008, 27(2), 151.
• Fa T. Pathology and Genetics. Tumours of the breast and female genital organs. Peritoneal tumours, 2003, 197-202.
• Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum‐based chemotherapy. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2000, 88(11), 2584-2589.
• Czernobilsky B, Silverman BB, Enterline HT. Clear‐cell carcinoma of the ovary. A clinicopathologic analysis of pure and mixed forms and comparison with endometrioid carcinoma. Cancer, 1970, 25(4), 762-772.
• Kurman RJ, Craig JM. Endometrioid and clear cell carcinoma of the ovary. Obstetrical & Gynecological Survey, 1973, 28(1), 67-69.
• Brescia RJ, Dubin N, Demopoulos RI. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists, 1989, 8(2), 132-138.